Phathom Pharmaceuticals, Inc. (PHAT)
PHAT Stock Price Chart
Explore Phathom Pharmaceuticals, Inc. interactive price chart. Choose custom timeframes to analyze PHAT price movements and trends.
PHAT Company Profile
Discover essential business fundamentals and corporate details for Phathom Pharmaceuticals, Inc. (PHAT) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
25 Oct 2019
Employees
427.00
Website
https://www.phathompharma.comCEO
Steven L. Basta
Description
Phathom Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. The company has the rights in the United States, Europe, and Canada to vonoprazan, a potassium-competitive acid blocker (P-CAB) that blocks acid secretion in the stomach. It is also developing vonoprazan, which is in Phase III clinical trials for the treatment of erosive gastroesophageal reflux disease; and in combination with antibiotics for the treatment of Helicobacter pylori infection. Phathom Pharmaceuticals, Inc. was incorporated in 2018 and is headquartered in Florham Park, New Jersey.
PHAT Financial Timeline
Browse a chronological timeline of Phathom Pharmaceuticals, Inc. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 29 Apr 2026
Upcoming earnings on 6 Nov 2025
EPS estimate is -$0.32, while revenue estimate is $47.03M.
Earnings released on 7 Aug 2025
EPS came in at -$0.79 falling short of the estimated -$0.76 by -3.95%, while revenue for the quarter reached $39.50M , missing expectations by -15.55%.
Earnings released on 1 May 2025
EPS came in at -$1.07 falling short of the estimated -$1.06 by -0.94%, while revenue for the quarter reached $28.52M , missing expectations by -19.99%.
Earnings released on 6 Mar 2025
EPS came in at -$0.79 surpassing the estimated -$1.29 by +38.76%, while revenue for the quarter reached $29.66M , beating expectations by +2.15%.
Earnings released on 7 Nov 2024
EPS came in at -$1.32 surpassing the estimated -$1.57 by +15.92%, while revenue for the quarter reached $16.35M , missing expectations by -36.55%.
Earnings released on 8 Aug 2024
EPS came in at -$1.25 falling short of the estimated -$1.20 by -4.17%, while revenue for the quarter reached $7.32M , beating expectations by +26.06%.
Earnings released on 9 May 2024
EPS came in at -$1.42 surpassing the estimated -$1.43 by +0.70%, while revenue for the quarter reached $1.91M , missing expectations by -6.73%.
Earnings released on 7 Mar 2024
EPS came in at -$0.80 surpassing the estimated -$0.92 by +13.04%, while revenue for the quarter reached $682.00K , beating expectations by +66.34%.
Earnings released on 9 Nov 2023
EPS came in at -$0.76 surpassing the estimated -$0.95 by +20.00%.
Earnings released on 10 Aug 2023
EPS came in at -$0.84 surpassing the estimated -$0.95 by +11.58%.
Earnings released on 10 May 2023
EPS came in at -$0.89 surpassing the estimated -$1.34 by +33.58%.
Earnings released on 28 Feb 2023
EPS came in at -$1.33 surpassing the estimated -$1.50 by +11.33%.
Earnings released on 8 Nov 2022
EPS came in at -$1.32 matching the estimated -$1.32.
Earnings released on 2 Aug 2022
EPS came in at -$1.33 falling short of the estimated -$1.03 by -29.13%.
Earnings released on 10 May 2022
EPS came in at -$1.07 falling short of the estimated -$0.97 by -10.31%.
Earnings released on 1 Mar 2022
EPS came in at -$0.95 falling short of the estimated -$0.86 by -10.47%.
Earnings released on 8 Nov 2021
EPS came in at -$0.98 falling short of the estimated -$0.78 by -25.64%.
Earnings released on 10 Aug 2021
EPS came in at -$1.00 surpassing the estimated -$1.07 by +6.54%.
Earnings released on 11 May 2021
EPS came in at -$0.96 surpassing the estimated -$1.11 by +13.51%.
Earnings released on 30 Mar 2021
EPS came in at -$1.58 falling short of the estimated -$0.93 by -69.89%.
Earnings released on 10 Nov 2020
EPS came in at -$1.02 falling short of the estimated -$0.68 by -50.00%.
PHAT Stock Performance
Access detailed PHAT performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.